Answers are grounded in this paper and cite their sources.
Case report reveals pseudoprogression in advanced gastric cancer following CAR-T cell therapy, suggesting new insights for treatment implications.
We reported the pseudoprogression in an elderly patient with advanced gastric cancer after chimeric antigen receptor (CAR)-T cell therapy. The hepatic metastases enlarged 1 month after CAR-T cell infusion and then shrunk the next month as seen through computed tomography scanning. Based on a comprehensive evaluation that includes imaging, pathology, serum tumor markers, and clinical symptoms, we arrived at a diagnosis of pseudoprogression after CAR-T cell therapy, which has not been reported in previous studies. In this report, we provide detailed descriptions of the patient's clinical presentation, imaging findings, treatment process, and follow-up outcomes. We believe that this case holds important implications for CAR-T cell therapy research and offers valuable insights for clinical practice.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: